Function of Long Noncoding RNAs in Glioma Progression and Treatment Based on the Wnt/β-Catenin and PI3K/AKT Signaling

Related Experiment Video

Updated: Jul 15, 2025

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.7K

Hanyun Li1, Jilan Liu2, Xianyun Qin2

  • 1Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.

Cellular and Molecular Neurobiology
|September 25, 2023
PubMed

Insights

Long noncoding RNAs (lncRNAs) are crucial in glioma progression and drug resistance. This review highlights their role in Wnt/β-catenin and PI3K/Akt pathways, offering new therapeutic targets for glioblastoma.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Gliomas, particularly glioblastoma (GBM), are aggressive central nervous system tumors with poor prognosis.
  • Existing therapies for GBM face challenges due to rapid progression, short survival, and therapy resistance.
  • Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in various cancers, including glioma.

Purpose of the Study:

  • To systematically review the role of lncRNAs in glioma malignant progression.
  • To assess the involvement of lncRNAs in glioblastoma drug resistance.
  • To focus on the function of lncRNAs within the Wnt/β-catenin and PI3K/Akt signaling pathways.

Main Methods:

  • Systematic literature review of research on glioma, lncRNAs, and key signaling pathways.
  • Analysis of studies investigating the aberrant expression and function of lncRNAs in glioma cells.
  • Examination of evidence linking lncRNAs to drug resistance mechanisms and biological behaviors in glioma.

Main Results:

  • lncRNAs are aberrantly expressed in glioma cells and influence malignant behaviors like proliferation, migration, invasion, and apoptosis.
  • lncRNAs play a significant role in mediating drug resistance in glioma by regulating pathways such as Wnt/β-catenin and PI3K/Akt.
  • Specific lncRNAs demonstrate critical functions within these classical signaling pathways, impacting glioma's aggressive nature.

Conclusions:

  • lncRNAs are key regulators of glioma progression and drug resistance.
  • Targeting lncRNAs involved in the Wnt/β-catenin and PI3K/Akt pathways presents a promising therapeutic strategy for glioblastoma.
  • Further research into lncRNA functions can uncover novel therapeutic targets for improved glioma treatment.
Keywords:
Malignant progressionPI3K/AktTherapy resistanceWnt/β-cateninlncRNAs

More Related Videos

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

7.9K
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

15.9K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.8K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.3K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K